In 2000, Steven Austad, a biologist, declared that “the first 150-year-old person is probably alive right now.” His optimism echoes that of futurists like Aubrey de Grey, who claims there is a greater than 50 percent chance a 40‑year‑old today will never die of old age. Researchers are probing the biological hallmarks of aging: telomeres shorten as cells divide, mitochondria lose efficiency, proteins misfold, DNA‑repair mechanisms falter, senescent “zombie” cells accumulate, and stem cells deplete. Experts such as Jaime Justice, Stephen Kritchevsky and John Newman explain how these changes drive age‑related diseases. Emerging interventions include senolytics to clear senescent cells, epigenetic reprogramming to reset gene expression, and repurposing FDA‑approved drugs and diabetes medications. XPRIZE Healthspan and ARPA‑H are funding studies on metabolism, inflammation, tissue repair and neural protection. While laboratory successes are promising, realistic life‑span extension remains an ongoing scientific quest.
What are senolytics and how could they impact aging?
Senolytics are experimental drugs that target and clear senescent cells, which contribute to inflammation and tissue dysfunction. By removing these “zombie” cells, senolytics aim to reduce age‑related diseases and possibly slow the overall aging process. Early research shows promise in lab animals, and several biotech firms are testing them in humans.
Source: New York Times Top Stories · Summarized by HeadlinesBriefing